Blar i forfatter "Farstad, Inger Nina"

Viser treff 1-2 av 2

    • AXL inhibition improves BRAF-targeted treatment in melanoma 

      Nyakas, Marta Sølvi; Fleten, Karianne Giller; Haugen, Mads Haugland; Engedal, Nikolai; Sveen, Christina; Farstad, Inger Nina; Flørenes, Vivi Ann; Prasmickaite, Lina; Mælandsmo, Gunhild Mari; Vasiliauskaite, Kotryna (Journal article; Tidsskriftartikkel; Peer reviewed, 2022)
      More than half of metastatic melanoma patients receiving standard therapy fail to achieve a long-term survival due to primary and/or acquired resistance. Tumor cell ability to switch from epithelial to a more aggressive mesenchymal phenotype, attributed with AXL<sup>high</sup> molecular profle in melanoma, has been recently linked to such event, limiting treatment efcacy. In the current study, ...

    • A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases 

      Flørenes, Vivi Ann; Flem-Karlsen, Karine; McFadden, Erin; Bergheim, Inger Riise; Nygaard, Vigdis; Nygård, Vegard Mokleiv; Farstad, Inger Nina; Øy, Geir Frode; Emilsen, Elisabeth; Fleten, Karianne Giller; Ree, Anne Hansen; Flatmark, Kjersti; Gullestad, Hans Petter; Hermann, Robert; Ryder, Truls; Wernhoff, Patrik; Mælandsmo, Gunhild Mari (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-05-13)
      Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) <i>ex vivo</i> drug efficacy assay, exposing disaggregated cells from 38 freshly harvested melanoma lymph node metastases and 21 patient derived ...